All articles tagged with #pancreatic cancer
At a European pancreatic cancer conference, experts hailed the anticipated launch of daraxonrasib as a potential milestone that could reshape care, echoing the impact of checkpoint inhibitors. But they warned the new therapy would bring opportunities and challenges—from access and pricing to real-world effectiveness and how it will be integrated into standard treatment and combination strategies as data emerge.
A new pancreatic cancer drug, daraxonrasib, has shown the ability to double median survival in advanced cases versus chemotherapy, fueling optimism about treating the disease earlier. At UC San Diego’s Moores Cancer Center, researchers note that early intervention could maximize benefits as part of PRECEDE, a global program screening at‑risk individuals with regular blood tests and imaging across 65 centers, with about 12,000 of 20,000 enrolled and roughly 75% of detected cases currently found at stage I. AI in imaging is anticipated to boost early detection, while the FDA has granted expanded access to the drug for patients not eligible for trials. Experts envision “interception studies” that could use RAS inhibitors earlier to prevent spread, potentially combining resection with targeted therapy for even better outcomes.
Harvard-trained gastroenterologist Dr. Saurabh Sethi highlights seven subtle signals that may indicate pancreatic cancer: persistent itching from bile-duct blockage; sudden changes in appetite or nausea; new jaundice; a dull mid-back ache; pale, oily or floating stools from impaired fat digestion; unexplained weight loss; and onset of diabetes after age 50. While none of these alone confirms cancer, persistent, unexplained symptoms should prompt medical evaluation, since early signs are often vague and time-sensitive tests (history, exam, bloodwork, imaging) are used to investigate.
Researchers at Florida A&M University tested polyisoprenylated cysteinyl amide inhibitors (PCAIs) against pancreatic cancer cells to disrupt mutant KRAS signaling. The leading compound NSL-YHJ-2-27 blocked more than 90% of cell migration at low concentrations, altered gene and protein markers related to movement, disrupted actin filaments, and dismantled 3D mini-tumor models; however, these findings are limited to lab studies and require animal testing and safety assessment before any human trials.
Researchers found experimental PCAIs kill pancreatic cancer cells and block their spread by hyperactivating MAPK and PI3K/AKT pathways, triggering ROS buildup and apoptosis; the leading compound NSL-YHJ-2-27 cut migration by over 90% at 1 µM and disrupted tumor spheroids, suggesting potential against several KRAS mutations, though further research is needed.
A Washington Post guest columnist undergoing chemotherapy for pancreatic cancer longs for her Holocaust-survivor father’s guidance and voice. As she confronts fear, she reflects on his endurance and learns a deeper lesson about resilience and meaning, reframing her own battle with cancer beyond statistics.
Researchers at Emory University’s Winship Cancer Institute and Piedmont Atlanta Hospital are testing daraxonrasib, an experimental pancreatic cancer drug, after FDA early-access approval; early results show tumor shrinkage with fewer side effects than standard chemotherapy, offering hope for patients facing one of the deadliest cancers.
A phase 3 trial published in the New England Journal of Medicine finds the oral RAS-inhibitor daraxonrasib significantly improves survival for metastatic pancreatic cancer, with a median of 13.2 months versus 6.7 months with chemotherapy; the FDA has granted an early-access program ahead of potential approval later in 2026, marking a potential paradigm shift by directly targeting mutant RAS to halt cancer growth.
A two-drug combo of Tango Therapeutics’ vopimetostat and Revolution Medicines’ daraxonrasib produced durable responses in the large majority of pancreatic cancer patients in an early-stage trial, prompting Tango to advance the approach to a Phase 3 study.
A Yale study finds oleic acid from olive oil can fuel pancreatic ductal adenocarcinoma via ferroptosis, while polyunsaturated fats may slow disease; separately, Mayo Clinic's REDMOD AI can detect pre-diagnostic pancreatic cancer on routine CTs with about 73% sensitivity; CNIO reports a triple-drug combo blocking RAF1, EGFR, and STAT3 that eliminates tumors in experimental models, highlighting advances in precision nutrition, early detection, and combination therapies against this deadly cancer.
At the 2026 ASCO meeting, a line graph showing daraxonrasib nearly doubling median survival for a form of advanced pancreatic cancer sparked a standing ovation, illustrating a broader cancer turn: US cancer deaths have fallen 34% since 1991 and the five-year survival for all cancers reached about 70% for those diagnosed 2015–2021, driven by immunotherapy, vaccines, and CAR‑T therapy; yet high drug costs and, more worryingly, funding cuts to NIH/NSF risk slowing the scientific engine behind these gains.
At ASCO 2026, researchers showcased ‘smart’ drugs that lift cancer cells’ invisibility cloaks to boost immunotherapy, with GRWD5769 plus cemiplimab shrinking tumors across several cancer types; other agents like ivonescimab and ozekibart show promise. A daily pill, daraxonrasib, doubled survival in metastatic pancreatic cancer, and mezigdomide added to therapy extended progression-free survival in multiple myeloma. A genomic test could allow many breast cancer patients to skip chemotherapy, while durvalumab added to chemoradiation may spare bladder-sparing surgery. Yet the Galleri multi-cancer test failed to reduce late-stage diagnoses, and rising incidence plus a looming cancer-care workforce gap stress health systems. Lifestyle changes such as better sleep and yoga may also improve outcomes for patients and survivors.
This week’s health roundup highlights a pancreatic cancer drug that nearly doubles survival in a pivotal trial, suggests everyday tasks could help detect dementia earlier, shares promising results from a skin-cancer vaccine, and notes new influenza research on different viral entry strategies, alongside other stories on depression treatment and stroke guidance.
Patients with pancreatic cancer are pursuing Revolution Medicines' experimental drug daraxonrasib through expanded-access programs as the company nears potential approval. While there is optimism the treatment could extend lives, demand is surging and production may not keep up, raising concerns about who receives the drug first and how access will be allocated.
Revolution Medicines’ daraxonrasib is expected to gain FDA approval for metastatic pancreatic cancer soon and could rapidly become the standard second-line therapy, with discussions about expanding use to newly diagnosed metastatic cases; the main gating factor is the speed of FDA submission.